Q-omics provides the consensus-scored EIF4BP1 profile across patient tissues and cancer cell-line models. EIF4BP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, EIF4BP1 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, EIF4BP1 RNA expression shows 4,457 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight MESO, BRCA, and OV as cancer lineages where EIF4BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4BP1 survival associations across molecular data types. EIF4BP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4BP1 RNA expression–survival associations across cancer types. High EIF4BP1 expression shows unfavorable associations in MESO, PAAD, STAD and CESC, but favorable associations in ESCA and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for EIF4BP1 RNA expression.
This table summarizes EIF4BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4BP1 shows lower tumor expression in BRCA and higher tumor expression in KIRP, ESCA and KIRC. The BRCA box plot shows higher EIF4BP1 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p = .011).
This table shows molecular features associated with EIF4BP1 in patient tissues and cancer cell lines. In patient samples, EIF4BP1 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
